Hepatitis C - Seeing Results

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Starts On: 7/1/2019: 12:00 AM
Ends On: 6/30/2020: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.5


Jeffrey S. Crippin, MD
Professor, Medicine
Marilyn Bornefeld Endowed Chair in Gastrointestinal Research and Treatment
Medical Director, Liver Transplantation
Associate Chairman for Clinical Programs
Financial Relationships:
- Consulting/Advisory Committees: Centene Corporation, Medimpact, Merck & Company, Transplant Management Group, AbbVie, Inc
- Speakers Bureau/Honoraria: Intercept Pharmaceuticals, Gilead Sciences, Merck & Company, Salix Pharmaceuticals, AbbVie, Inc, Dova Pharmaceuticals
- Ownership Interest/Stock Equity: AbbVie, Inc

Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, 16th Galaxy of Gastroenterology, November 2-3, 2018, which was supported in part by Synergy Pharmaceuticals Inc., Takeda Pharmaceuticals, and Olympus Corporation of the Americas.

Planning Committee

C. Prakash Gyawali, MD, MRCP, Course Chair
Financial Relationships:
Consulting/ Advisory Committees: Medtronic, Ironwood Pharmaceuticals, Torax, Quintiles
Research Support/Grants: Allergan, Inc, Ironwood Pharmaceuticals
Speakers' Bureaus/Honoraria: Diversitak, Medtronic

Gregory S. Sayuk, MD, MPH, Course Chair
Financial Relationships:
Consulting/ Advisory Committees: Synthetic Biologics, Synergy Pharmaceuticals
Speakers' Bureaus/Honoraria: Allergan, Inc

Jill Elwing, MD, Independent Reviewer
Financial Relationships: Reviewer has nothing to disclose

Laura Haroian, RN, MSN, Nurse Planner
Financial Relationships: Planner has nothing to disclose.

Gillian M. Powderly, PharmD, Pharmacist Planner
VA St. Louis Health Care System-John Cochran Division
Financial Relationships: Planner has nothing to disclose.

Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • Name the different treatment options for chronic hepatitis C.
  • Recognize the contraindications to treatment with specific conditions and certain agents.
  • Discuss the use of HCV antiviral therapy following organ transplantation.
  • Discuss the prevalence of chronic hepatitis C.
Additional Information:
Target Audience: This course is designed for primary care physicians, gastroenterologists, gastrointestinal surgeons and their associates who participate in the care of patients with gastrointestinal and hepatic disorders. The course will also be of value to technicians, nurses and physicians who participate in endoscopy, gastrointestinal motility procedures, and pH-monitoring procedures.

Publication Date: July 1, 2019
Expiration Date: June 30, 2020
Accreditation Information:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Categories: Gastroenterology

Powered By AI 4.5